UNSPSC 51142537: Piroheptine

This classification denotes an antiparkinsonian agent with the molecular formula C22H25N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AR6Y753ARL, chemically known as 3-(10,11-dihydro-5h-dibenzo(a,d)cyclohepten-5-ylidene)-1-ethyl-2-methylpyrrolidine but generally known as piroheptine, which bears US NIH Compound Identifier 4854. European Medicines Agency schedules Piroheptine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09931MIG.

UNSPSC 51142537 Piroheptine, a Commodity code, does not align with the recent state and local contract opportunities tagged under it. The code nominally refers to a specific pharmaceutical compound, yet the recent solicitations cover naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products — none of which are piroheptine-specific acquisitions.

The mismatch between the code's nominal scope and actual procurement activity suggests that this Commodity code sees little relevant recent activity in state and local government procurement. The three opportunities posted between January and June 2026 represent different pharmaceutical procurement models — unit purchases for community health (Seminole County, Florida), information gathering on pharmacy benefit program restructuring (Texas HHS Commission), and cooperative purchasing of generic pharmaceuticals across multiple jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance). None involves piroheptine as a target product or service line. Until state and local procurement systems properly categorize pharmaceutical acquisitions by active ingredient or therapeutic class, this code will remain a poor signal for vendors pursuing opportunities in pharmaceutical supply to state and local government entities.